Use of Upadacitinib in Two Cases of Refractory Systemic Lupus Erythematosus
May 2025
in “
The Journal of Rheumatology
”
Studysummary In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jrheum.org →